$AEON
AEON Biopharma, Inc. Stock $aeon

$aeon Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000155837024011896 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.044M	$3.321M	$4.946M
YoY Change	-44.25%	-32.85%
% of Gross Profit
Research & Development	$972.0K	$4.439M	$9.025M
YoY Change	-84.77%	-50.81%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.016M	-$153.5M	$3.530M
YoY Change	-106.94%	-4447.68%	726.31%
Operating Profit	-$4.016M	$153.5M	-$3.527M
YoY Change	-106.94%	-4451.97%	725.49%
Interest Expense			-$320.0K
YoY Change			-113.85%
% of Operating Profit
Other Income/Expense, Net	-$2.155M	$10.64M	-$324.2K
YoY Change	-84.6%	-3382.08%	-114.02%
Pretax Income	-$6.171M	$164.1M	-$3.851M
YoY Change	-114.06%	-4361.9%	-304.38%
Income Tax			$91.66K
% Of Pretax Income
Net Earnings	-$6.171M	$164.1M	-$3.942M
YoY Change	-114.06%	-4262.81%	-311.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.16	$4.22	-$0.11
Diluted Earnings Per Share	-$0.16	$4.22	-$0.44
COMMON SHARES
Basic Shares Outstanding	39.52M	39.12M	138.8M
Diluted Shares Outstanding	39.52M	38.84M	138.8M

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments			$400.0K
YoY Change			5054.64%
Cash & Equivalents	$500.0K	$3.400M	$441.4K
Short-Term Investments
Other Short-Term Assets			$200.0K
YoY Change			-16.85%
Inventory
Prepaid Expenses			$150.7K
Receivables
Other Receivables
Total Short-Term Assets	$2.371M	$4.019M	$592.1K
YoY Change	-85.98%	578.77%	138.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$258.0K	$282.0K
YoY Change	-27.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$21.20M
YoY Change			-92.33%
Other Assets	$29.00K	$29.00K
YoY Change	0.0%
Total Long-Term Assets	$1.633M	$1.715M	$21.19M
YoY Change	130.65%	-91.91%	-92.33%
TOTAL ASSETS
Total Short-Term Assets	$2.371M	$4.019M	$592.1K
Total Long-Term Assets	$1.633M	$1.715M	$21.19M
Total Assets	$4.004M	$5.734M	$21.79M
YoY Change	-77.27%	-73.68%	-92.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.630M	$3.030M	$7.000M
YoY Change	15.38%	-56.71%	724.68%
Accrued Expenses			$400.0K
YoY Change			300.0%
Deferred Revenue
YoY Change
Short-Term Debt			$1.000M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.73M	$10.43M	$9.461M
YoY Change	-24.34%	10.23%	879.6%
LONG-TERM LIABILITIES
Long-Term Debt			$0.00
YoY Change
Other Long-Term Liabilities			$2.600M
YoY Change			-78.04%
Total Long-Term Liabilities			$2.600M
YoY Change			-78.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.73M	$10.43M	$9.461M
Total Long-Term Liabilities			$2.600M
Total Liabilities	$36.09M	$33.68M	$12.05M
YoY Change	-74.1%	179.43%	-5.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$433.7M	-$427.5M	-$11.49M
YoY Change	2.51%	3619.37%	-7.32%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity			-$11.46M
YoY Change
Total Liabilities & Shareholders Equity	$4.004M	$5.734M	$21.79M
YoY Change	-77.27%	-73.68%	-92.12%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$6.171M	$164.1M	-$3.942M
YoY Change	-114.06%	-4262.81%	-311.15%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities			-$950.0K
YoY Change			499.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$80.00K
YoY Change
Cash From Investing Activities			$80.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			850.0K
YoY Change
NET CHANGE
Cash From Operating Activities			-950.0K
Cash From Investing Activities			80.00K
Cash From Financing Activities			850.0K
Net Change In Cash			-20.00K
YoY Change			-87.38%
FREE CASH FLOW
Cash From Operating Activities			-$950.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q2	us-gaap	Debt Instrument Measurement Input Extensible List DebtInstrumentMeasurementInputExtensibleList	http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2023Q2	us-gaap	Debt Instrument Measurement Input Extensible List DebtInstrumentMeasurementInputExtensibleList	http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2024Q2	us-gaap	Debt Instrument Measurement Input Extensible List DebtInstrumentMeasurementInputExtensibleList	http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2024Q2	us-gaap	Debt Instrument Measurement Input Extensible List DebtInstrumentMeasurementInputExtensibleList	http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
	dei	Entity Central Index Key EntityCentralIndexKey	0001837607
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39122238
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39122238
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37159600
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40021
	dei	Entity Registrant Name EntityRegistrantName	AEON Biopharma, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3940478
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Park Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1750
	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
	dei	City Area Code CityAreaCode	949
	dei	Local Phone Number LocalPhoneNumber	354-6499
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Class A common stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	AEON
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39522238
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3442000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5158000
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	577000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1064000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	4019000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6222000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	282000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1404000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	262000
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000
CY2024Q2	us-gaap	Assets Assets	5734000
CY2023Q4	us-gaap	Assets Assets	6845000
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3030000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3388000
CY2024Q2	aeon	Accrued Clinical Trails Expenses Current AccruedClinicalTrailsExpensesCurrent	2333000
CY2023Q4	aeon	Accrued Clinical Trails Expenses Current AccruedClinicalTrailsExpensesCurrent	5128000
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1248000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	943000
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3818000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10429000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13049000
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	13292000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1262000
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1467000
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1447000
CY2024Q2	aeon	Contingent Consideration Liability ContingentConsiderationLiability	6886000
CY2023Q4	aeon	Contingent Consideration Liability ContingentConsiderationLiability	104350000
CY2024Q2	aeon	Forward Purchase Agreement And Derivative Liability ForwardPurchaseAgreementAndDerivativeLiability	345000
CY2023Q4	aeon	Forward Purchase Agreement And Derivative Liability ForwardPurchaseAgreementAndDerivativeLiability	41043000
CY2024Q2	us-gaap	Liabilities Liabilities	33681000
CY2023Q4	us-gaap	Liabilities Liabilities	159889000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39122238
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37159600
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	4000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	399557000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	381264000
CY2023Q4	aeon	Subscription Receivables SubscriptionReceivables	-60710000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427508000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-473602000
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-27947000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-153044000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5734000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6845000
CY2024Q2	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q2	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3321000
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4946000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7970000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8787000
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4439000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9025000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10172000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18230000
CY2024Q2	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	-161233000
	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	-97464000
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	-153473000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	13971000
	us-gaap	Operating Expenses OperatingExpenses	-79322000
	us-gaap	Operating Expenses OperatingExpenses	27017000
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	153473000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13971000
	us-gaap	Operating Income Loss OperatingIncomeLoss	79322000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27017000
CY2024Q2	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	1795000
CY2023Q2	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-1453000
	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	1708000
	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-6110000
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5905000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14999000
CY2024Q2	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	-2905000
	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	20012000
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	75000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	109000
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10639000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1408000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33228000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6001000
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	164112000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15379000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	46094000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33018000
CY2024Q2	aeon	Loss And Comprehensive Loss LossAndComprehensiveLoss	164112000
CY2023Q2	aeon	Loss And Comprehensive Loss LossAndComprehensiveLoss	-15379000
	aeon	Loss And Comprehensive Loss LossAndComprehensiveLoss	46094000
	aeon	Loss And Comprehensive Loss LossAndComprehensiveLoss	-33018000
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.22
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.22
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38843627
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38843627
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38055850
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38055850
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-198381000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	164112000
CY2024Q2	aeon	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	4629000
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1693000
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-27947000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-286692000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-15379000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1145000
CY2023Q2	aeon	Stockholders Equity Period Increase Decrease Through Debit Extinguishment Due To Warrant Modification StockholdersEquityPeriodIncreaseDecreaseThroughDebitExtinguishmentDueToWarrantModification	17036000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-283890000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-153044000
	us-gaap	Net Income Loss NetIncomeLoss	46094000
	aeon	Termination Of Forward Purchase Agreements TerminationOfForwardPurchaseAgreements	60710000
	aeon	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	14979000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3314000
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-27947000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-270413000
	us-gaap	Net Income Loss NetIncomeLoss	-33018000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2505000
	aeon	Stockholders Equity Period Increase Decrease Through Debit Extinguishment Due To Warrant Modification StockholdersEquityPeriodIncreaseDecreaseThroughDebitExtinguishmentDueToWarrantModification	17036000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-283890000
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Profit Loss ProfitLoss	46094000
	us-gaap	Profit Loss ProfitLoss	-33018000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000
	us-gaap	Share Based Compensation ShareBasedCompensation	3314000
	us-gaap	Share Based Compensation ShareBasedCompensation	2505000
	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	1708000
	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-6110000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14999000
	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	20012000
	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	-97464000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-487000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-358000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1460000
	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-2263000
	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	4656000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-122000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	17000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16716000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21143000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	15000000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	14000000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15000000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14000000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1716000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7143000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5158000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9746000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3442000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2603000
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3400000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427500000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities and convertible notes. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., LTD. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See <a href="#Note7_Commitments_Contingencies"><span style="font-style:normal;font-weight:normal;">Note 7 Commitments and Contingencies</span></a> for a discussion of the Daewoong Agreement.</p>
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	220000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	282000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
	us-gaap	Legal Fees LegalFees	1961000
CY2023	us-gaap	Legal Fees LegalFees	1867000
CY2024Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	278000
CY2024Q2	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	444000
CY2023Q4	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	33000
CY2024Q2	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	710000
CY2023Q4	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	843000
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3818000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-15379000
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Net Income Loss NetIncomeLoss	-33018000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	164112000
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38843627
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38843627
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.22
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.22
	us-gaap	Net Income Loss NetIncomeLoss	46094000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38055850
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38055850
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.21
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28652560
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32121964
CY2023Q3	aeon	Number Of Shares To Be Received Prior To Merger NumberOfSharesToBeReceivedPriorToMerger	2.328
CY2024Q2	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	1800000
	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	1700000
CY2023Q2	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	-1500000
	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	-6100000
CY2024Q2	us-gaap	Convertible Debt ConvertibleDebt	15000000.0
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	0
CY2024Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	13300000
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0
CY2024Q2	aeon	Subscription Receivable And Derivative Liability SubscriptionReceivableAndDerivativeLiability	0
	aeon	Subscription Receivable And Derivative Liability SubscriptionReceivableAndDerivativeLiability	20300000
CY2023Q2	aeon	Number Of Additional Shares To Be Issued NumberOfAdditionalSharesToBeIssued	16000000
CY2023Q2	aeon	Threshold Increase In Episodic Migraine Contingent Consideration Shares ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	11000000
CY2023Q2	aeon	Number Of Chronic Migraine Contingent Consideration Shares By Increase In Episodic Migraine Contingent Consideration Shares NumberOfChronicMigraineContingentConsiderationSharesByIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares	1000000
CY2023Q2	aeon	Minimum Number Of Chronic Migraine Contingent Consideration Shares After Reduction MinimumNumberOfChronicMigraineContingentConsiderationSharesAfterReduction	0
CY2024Q2	aeon	Contingent Consideration Liability ContingentConsiderationLiability	6900000
CY2023Q4	aeon	Contingent Consideration Liability ContingentConsiderationLiability	104400000
CY2024Q2	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	-161200000
	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	-97500000
CY2024Q1	aeon	Class Of Warrant Or Right Redemption Price ClassOfWarrantOrRightRedemptionPrice	0.10
CY2024Q2	aeon	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1001950
	aeon	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1962638
CY2024Q2	aeon	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	4600000
	aeon	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	15000000.0
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14479999
	aeon	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-10283637
	aeon	Class Of Warrant Or Right Cancelled ClassOfWarrantOrRightCancelled	-207410
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3988952
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	159000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	175000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	297000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	307000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	318000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	328000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1584000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	188000
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1396000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1262000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1404000
CY2024Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y6M
CY2024Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.043
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	72000
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	68000
	us-gaap	Operating Lease Cost OperatingLeaseCost	116000
	us-gaap	Operating Lease Cost OperatingLeaseCost	138000
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	80000
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	77000
	us-gaap	Operating Lease Payments OperatingLeasePayments	159000
	us-gaap	Operating Lease Payments OperatingLeasePayments	154000
CY2023Q3	aeon	Deferred Underwriting Fee DeferredUnderwritingFee	1250000
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39122238
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	30394494
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38876675
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1100000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2500000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.041
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0366
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001558370-24-011896-index-headers.html	Edgar Link	pending
0001558370-24-011896-index.html	Edgar Link	pending
0001558370-24-011896.txt	Edgar Link	pending
0001558370-24-011896-xbrl.zip	Edgar Link	pending
aeon-20240630.xsd	Edgar Link	pending
aeon-20240630x10q.htm	Edgar Link	pending
aeon-20240630xex31d1.htm	Edgar Link	pending
aeon-20240630xex32d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
aeon-20240630_def.xml	Edgar Link	unprocessable
aeon-20240630x10q_htm.xml	Edgar Link	completed
aeon-20240630_lab.xml	Edgar Link	unprocessable
aeon-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aeon-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AEON
AEON Biopharma, Inc. Stock $aeon

2024 Q3 Form 10-Q Financial Statement

#000155837024011896 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AEON AEON Biopharma, Inc. Stock $aeon

2024 Q3 Form 10-Q Financial Statement

#000155837024011896 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AEON
AEON Biopharma, Inc. Stock $aeon